Leber Congenital Amaurosis (LCA) is an inherited eye condition which results in almost complete blindness at birth or during the first years of life because of the inherited genetic defects in the functioning of the retina. LCA is inherited in an autosomal recessive pattern and it is one of the leading causes of congenital blindness. It targets the retina of the eye and can cause blindness as the child grows up to adulthood if the illness is not treated. Since its discovery, the LCA has advanced through various stages to embrace the ongoing discovery of gene therapies and other treatment that hold potential for its cure.

The lentiviral vectors market has seen considerable growth in recent years, driven by advancements in gene therapy and the increasing need for efficient delivery systems in genetic research and clinical applications. Lentiviral vectors, derived from the lentivirus, are particularly valuable for gene therapy due to their ability to integrate into the host genome and sustain long-term gene expression. This unique capability has led to their widespread adoption for treating genetic disorders, cancers, and other complex diseases, with the global market projected to expand at a substantial compound annual growth rate (CAGR) over the next decade.